This page has only limited features, please log in for full access.
In chronic kidney disease (CKD) patients, it would be desirable to reduce the intake of inorganic phosphate (P) rather than limit the intake of P contained in proteins. Urinary excretion of P should reflect intestinal absorption of P(inorganic plus protein-derived). The aim of the present study is to determine whether the ratio of urinary P to urinary urea nitrogen (P/UUN ratio) helps identify patients with a high intake of inorganic P.A cross-sectional study was performed in 71 patients affected by metabolic syndrome with CKD (stages 2–3) with normal serum P concentration. A 3-day dietary survey was performed to estimate the average daily amount and the source of P ingested. The daily intake ofPwas1086.5 ± 361.3mg/day; 64% contained in animal proteins, 22% in vegetable proteins, and 14% as inorganic P. The total amount of P ingested did not correlate with daily phosphaturia, but it did correlate with the P/UUN ratio (p < 0.018). Patients with the highest tertile of the P/UUN ratio >71.1 mg/g presented more abundant inorganic P intake (p < 0.038).The P/UUN ratio is suggested to be a marker of inorganic P intake. This finding might be useful in clinical practices to identify the source of dietary P and to make personalized dietary recommendations directed to reduce inorganic P intake.
María Pendón-Ruiz de Mier; Noemí Vergara; Cristian Rodelo-Haad; María López-Zamorano; Cristina Membrives-González; Rodrigo López-Baltanás; Juan Muñoz-Castañeda; Francisco Caravaca; Alejandro Martín-Malo; Arnold Felsenfeld; Eugenio De la Torre; Sagrario Soriano; Rafael Santamaría; Mariano Rodríguez. Assessment of Inorganic Phosphate Intake by the Measurement of the Phosphate/Urea Nitrogen Ratio in Urine. Nutrients 2021, 13, 292 .
AMA StyleMaría Pendón-Ruiz de Mier, Noemí Vergara, Cristian Rodelo-Haad, María López-Zamorano, Cristina Membrives-González, Rodrigo López-Baltanás, Juan Muñoz-Castañeda, Francisco Caravaca, Alejandro Martín-Malo, Arnold Felsenfeld, Eugenio De la Torre, Sagrario Soriano, Rafael Santamaría, Mariano Rodríguez. Assessment of Inorganic Phosphate Intake by the Measurement of the Phosphate/Urea Nitrogen Ratio in Urine. Nutrients. 2021; 13 (2):292.
Chicago/Turabian StyleMaría Pendón-Ruiz de Mier; Noemí Vergara; Cristian Rodelo-Haad; María López-Zamorano; Cristina Membrives-González; Rodrigo López-Baltanás; Juan Muñoz-Castañeda; Francisco Caravaca; Alejandro Martín-Malo; Arnold Felsenfeld; Eugenio De la Torre; Sagrario Soriano; Rafael Santamaría; Mariano Rodríguez. 2021. "Assessment of Inorganic Phosphate Intake by the Measurement of the Phosphate/Urea Nitrogen Ratio in Urine." Nutrients 13, no. 2: 292.
Acute kidney injury (AKI) occurs in 12-20% of multiple myeloma (MM) patients. Several studies have shown a reduction of free light chains (FLC) using hemodialysis with High-Cut-Off membranes. However, this technique entails albumin loss. Hemodiafiltration with ultrafiltrate regeneration is a technique that includes a process of adsorption. The aim of this study was to evaluate the effectiveness of hemodiafiltration with ultrafiltrate regeneration in reducing FLC levels without causing albumin loss. This is an observational study (2012 to 2018) including nine patients with MM (5 kappa, 4 lambda) and AKI. All patients were treated with chemotherapy and hemodiafiltration with ultrafiltrate regeneration. Blood Samples (pre and post-dialysis) and ultrafiltrate were collected pre and post-resin at 5 min after initiation of the session and 5 min before the end of the procedure. The serum levels of kappa and lambda were reduced by a 57.6 ± 10% and 33.5 ± 25% respectively. Serum albumin concentration remained unchanged after the procedure. In the ultrafiltrate, the mean FLC reduction ratio shortly after initiation of the dialysis procedure was: 99.2 and 97.06% for kappa and lambda respectively, and only 0.7% for albumin; and at the end of the session the percent reduction was: 63.7 and 33.62% for kappa and lambda respectively, and 0.015% for albumin. Patients clinical outcome was: 33.3% recovered renal function, 22.2% died during the first year and 44.4% required maintenance dialysis. Hemodiafiltration with ultrafiltrate regeneration reduces FLC levels without producing a significant loss of albumin; and, FLC removal is maintained throughout the session. Therefore, hemodiafiltration with ultrafiltrate regeneration may be considered an effective adjunctive therapy in patients with MM.
M. Victoria Pendón-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. BMC Nephrology 2020, 21, 227 .
AMA StyleM. Victoria Pendón-Ruiz De Mier, Raquel Ojeda, M. Antonia Álvarez-Lara, Ana Navas, Corona Alonso, Javier Caballero-Villarraso, Pedro Aljama, Miguel A. Álvarez, Sagrario Soriano, Mariano Rodríguez, Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. BMC Nephrology. 2020; 21 (1):227.
Chicago/Turabian StyleM. Victoria Pendón-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. 2020. "Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients." BMC Nephrology 21, no. 1: 227.
Background. Acute kidney injury (AKI) occurs in 12-20% of multiple myeloma (MM) patients. Several studies have shown a reduction of free light chains (FLC) using hemodialysis with High-Cut-Off membranes. However, this technique entails albumin loss. Hemodiafiltration with ultrafiltrate regeneration is a technique that includes a process of adsorption. The aim of this study was to evaluate the effectiveness of hemodiafiltration with ultrafiltrate regeneration in reducing FLC levels without causing albumin loss. Methods. This is an observational study (2012 to 2018) including nine patients with MM (5 kappa, 4 lambda) and AKI. All patients were treated with chemotherapy and hemodiafiltration with ultrafiltrate regeneration. Blood Samples (pre and post-dialysis) and ultrafiltrate were collected pre and post-resin at 5 minutes after initiation of the session and 5 minutes before the end of the procedure. Results. The serum levels of kappa and lambda were reduced by a 57.6±10% and 33.5±25% respectively. Serum albumin concentration remained unchanged after the procedure. In the ultrafiltrate, the mean FLC reduction ratio shortly after initiation of the dialysis procedure was: 99.2% and 97.06% for kappa and lambda respectively, and only 0.7% for albumin; and at the end of the session the percent reduction was: 63.7% and 33.62% for kappa and lambda respectively, and 0.015% for albumin. Patients clinical outcome was: 33.3% recovered renal function, 22.2% died during the first year and 44.4% required maintenance dialysis. Conclusions. Hemodiafiltration with ultrafiltrate regeneration reduces FLC levels without producing a significant loss of albumin; and, FLC removal is maintained throughout the session. Therefore, hemodiafiltration with ultrafiltrate regeneration may be considered an effective adjunctive therapy in patients with MM.
M. Victoria Pendon-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. 2020, 1 .
AMA StyleM. Victoria Pendon-Ruiz De Mier, Raquel Ojeda, M. Antonia Álvarez-Lara, Ana Navas, Corona Alonso, Javier Caballero-Villarraso, Pedro Aljama, Miguel A. Álvarez, Sagrario Soriano, Mariano Rodríguez, Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. . 2020; ():1.
Chicago/Turabian StyleM. Victoria Pendon-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. 2020. "Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients." , no. : 1.
Background Acute kidney injury (AKI) occurs in 12-20% of multiple myeloma (MM) patients. Several studies have shown a reduction of free light chains (FLC) using hemodialysis with High-Cut-Off membranes. However, this technique entails albumin loss. Hemodiafiltration with ultrafiltrate regeneration is a technique that includes a process of adsorption. The aim of this study was to evaluate the effectiveness of hemodiafiltration with ultrafiltrate regeneration in reducing FLC levels without causing albumin loss. Methods This is an observational study (2012 to 2018) including eleven patients with MM (6 kappa, 5 lambda) and AKI. All patients were treated with chemotherapy and hemodiafiltration with ultrafiltrate regeneration. Blood Samples (pre and post-dialysis) and ultrafiltrate were collected pre and post-resin at 5 minutes after initiation of the session and 5 minutes before the end of the procedure. Results The serum levels of kappa and lambda were reduced by a 53±14% and 33±22% respectively. Serum albumin concentration remained unchanged after the procedure. In the ultrafiltrate, the mean FLC reduction ratio shortly after initiation of the dialysis procedure was: 99.2% and 97.06% for kappa and lambda respectively, and only 0.7% for albumin; and at the end of the session the percent reduction was: 63.7% and 33.62% for kappa and lambda respectively, and 0.015% for albumin. Patients clinical outcome was: 36.4% recovered renal function, 18.2% died during the first year and 45.45% required maintenance dialysis. Conclusions Hemodiafiltration with ultrafiltrate regeneration reduces FLC levels without producing a significant loss of albumin; and, FLC removal is maintained throughout the session. Therefore, hemodiafiltration with ultrafiltrate regeneration may be considered an effective adjunctive therapy in patients with MM.
M. Victoria Pendon-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. 2020, 1 .
AMA StyleM. Victoria Pendon-Ruiz De Mier, Raquel Ojeda, M. Antonia Álvarez-Lara, Ana Navas, Corona Alonso, Javier Caballero-Villarraso, Pedro Aljama, Miguel A. Álvarez, Sagrario Soriano, Mariano Rodríguez, Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. . 2020; ():1.
Chicago/Turabian StyleM. Victoria Pendon-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. 2020. "Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients." , no. : 1.
Fibroblast Growth Factor 23 (FGF23) and Klotho play an essential role in the regulation of mineral metabolism, and both are altered as a consequence of renal failure. FGF23 increases to augment phosphaturia, which prevents phosphate accumulation at the early stages of chronic kidney disease (CKD). This effect of FGF23 requires the presence of Klotho in the renal tubules. However, Klotho expression is reduced as soon as renal function is starting to fail to generate a state of FGF23 resistance. Changes in these proteins directly affect to other mineral metabolism parameters; they may affect renal function and can produce damage in other organs such as bone, heart, or vessels. Some of the mechanisms responsible for the changes in FGF23 and Klotho levels are related to modifications in the Wnt signaling. This review examines the link between FGF23/Klotho and Wnt/β-catenin in different organs: kidney, heart, and bone. Activation of the canonical Wnt signaling produces changes in FGF23 and Klotho and vice versa; therefore, this pathway emerges as a potential therapeutic target that may help to prevent CKD-associated complications.
Juan Rafael Muñoz-Castañeda; Cristian Rodelo-Haad; Maria Victoria Pendon-Ruiz De Mier; Alejandro Martin-Malo; Rafael Santamaria; Mariano Rodriguez. Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease. Toxins 2020, 12, 185 .
AMA StyleJuan Rafael Muñoz-Castañeda, Cristian Rodelo-Haad, Maria Victoria Pendon-Ruiz De Mier, Alejandro Martin-Malo, Rafael Santamaria, Mariano Rodriguez. Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease. Toxins. 2020; 12 (3):185.
Chicago/Turabian StyleJuan Rafael Muñoz-Castañeda; Cristian Rodelo-Haad; Maria Victoria Pendon-Ruiz De Mier; Alejandro Martin-Malo; Rafael Santamaria; Mariano Rodriguez. 2020. "Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease." Toxins 12, no. 3: 185.
Background Acute kidney injury (AKI) occurs in 12-20% of multiple myeloma (MM) patients. Several studies have shown a reduction of free light chains (FLC) using hemodialysis with High-Cut-Off membranes. However, this technique entails albumin loss. Hemodiafiltration with ultrafiltrate regeneration is a technique that includes a process of adsorption. The aim of this study was to evaluate the effectiveness of hemodiafiltration with ultrafiltrate regeneration in reducing FLC levels without causing albumin loss. Methods This is an observational study (2012 to 2018) including eleven patients with MM (6 kappa, 5 lambda) and AKI. All patients were treated with chemotherapy and hemodiafiltration with ultrafiltrate regeneration. Blood Samples (pre and post-dialysis) and ultrafiltrate were collected pre and post-resin at 5 minutes after initiation of the session and 5 minutes before the end of the procedure. Results The serum levels of kappa and lambda were reduced by a 53±14% and 33±22% respectively. Serum albumin concentration remained unchanged after the procedure. In the ultrafiltrate, the mean FLC reduction ratio shortly after initiation of the dialysis procedure was: 99.2% and 97.06% for kappa and lambda respectively, and only 0.7% for albumin; and at the end of the session the percent reduction was: 63.7% and 33.62% for kappa and lambda respectively, and 0.015% for albumin. Patients clinical outcome was: 36.4% recovered renal function, 18.2% died during the first year and 45.45% required maintenance dialysis. Conclusions Hemodiafiltration with ultrafiltrate regeneration reduces FLC levels without producing a significant loss of albumin; and, FLC removal is maintained throughout the session. Therefore, hemodiafiltration with ultrafiltrate regeneration may be considered an effective adjunctive therapy in patients with MM.
M. Victoria Pendon-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. 2020, 1 .
AMA StyleM. Victoria Pendon-Ruiz De Mier, Raquel Ojeda, M. Antonia Álvarez-Lara, Ana Navas, Corona Alonso, Javier Caballero-Villarraso, Pedro Aljama, Miguel A. Álvarez, Sagrario Soriano, Mariano Rodríguez, Alejandro Martín-Malo. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. . 2020; ():1.
Chicago/Turabian StyleM. Victoria Pendon-Ruiz De Mier; Raquel Ojeda; M. Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A. Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo. 2020. "Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients." , no. : 1.
Los hallazgos más frecuentes de sospecha de insuficiencia renal crónica (IRC) son la elevación crónica de creatinina sérica o la disminución progresiva del filtrado glomerular (< 60 ml/minuto/1,73 m2). Ante la sospecha clínica de IRC, se debe realizar una historia clínica completa, recogiendo antecedentes personales, familiares y factores de riesgo de IRC. La anamnesis debe ir dirigida a la identificación de agentes etiológicos, signos y síntomas. Las pruebas complementarias que se deben realizar son: análisis de sangre, orina y ecografía renal. En primer lugar, se realizaría una ecografía renal para descartar una patología obstructiva e identificar anormalidades estructurales y, en segundo lugar, se hará un análisis de sangre y orina. Estas tres pruebas son necesarias para poder llevar a cabo un correcto diagnóstico de la IRC. The most common suspicious findings of chronic renal insufficiency (CRI) are chronic elevation in serum creatinine or progressive decline in glomerular filtration rate (< 60 ml/minute/1.73 m2). Complete clinical history (personal and familial history and CRI risk factors) has to be performed in case of CRI suspicion. The identification of etiological agents, signs and symptoms is the goal of anamnesis. The following complementary tests have to be performed: blood test, urine test and renal ultrasound. Firstly, in order to discard obstructive condition and to identify structural abnormalities, renal ultrasound is carried out. Next, blood and urine tests must be done. All these three tests are necessary to achieve the diagnosis of CRI.
M.V. Pendón Ruiz De Mier; V. García-Montemayor; C. Moyano Peregrín; S. Soriano Cabrera. Protocolo diagnóstico de la insuficiencia renal crónica. Medicine - Programa de Formación Médica Continuada Acreditado 2019, 12, 4702 -4704.
AMA StyleM.V. Pendón Ruiz De Mier, V. García-Montemayor, C. Moyano Peregrín, S. Soriano Cabrera. Protocolo diagnóstico de la insuficiencia renal crónica. Medicine - Programa de Formación Médica Continuada Acreditado. 2019; 12 (79):4702-4704.
Chicago/Turabian StyleM.V. Pendón Ruiz De Mier; V. García-Montemayor; C. Moyano Peregrín; S. Soriano Cabrera. 2019. "Protocolo diagnóstico de la insuficiencia renal crónica." Medicine - Programa de Formación Médica Continuada Acreditado 12, no. 79: 4702-4704.
La insuficiencia renal crónica (IRC) es una patología que afecta al 10% de la población española y supone una elevada morbilidad y mortalidad. La etiología de la IRC es multifactorial. Las principales causas son la diabetes mellitus, la hipertensión arterial y las glomerulonefritis. Los síntomas suelen ser inespecíficos y no aparecen hasta que la enfermedad está avanzada. El diagnóstico se establece en base al filtrado glomerular, análisis de orina y biopsia renal. En ocasiones, se realiza un diagnóstico con técnicas de imagen. Las complicaciones de la IRC incluyen anemia, alteraciones del metabolismo óseo y mineral, acidosis metabólica e incremento del riesgo cardiovascular. El tratamiento va encaminado a retrasar el deterioro de la función renal y evitar las complicaciones derivadas del mismo. Requiere hábitos de vida saludables y control de los factores de riesgo cardiovascular. Cuando el daño renal es irreversible, precisa tratamiento renal sustitutivo. Chronic renal insufficiency (CRI) is a condition that affects as many as 10% of Spanish population, and shows high morbidity and mortality rates. Regarding its etiology, CRI is a multifactorial condition. Diabetes mellitus, hypertension and glomerulonephritis are the most common causes. Symptomatology is non-specific, appearing in advanced stages of the disease. Diagnosis is supported on glomerular filtration rate, urine test and kidney biopsy. Imaging tests are used occasionally. CRI complications comprise anemia, altered bone and mineral metabolism, metabolic acidosis and increased cardiovascular risk. Treatment is guided to delay the deterioration in renal function and to avoid related complications: includes healthy life habits and control of cardiovascular risk factors. Replacement renal therapy is required when kidney damage is irreversible.
M.V. Pendón Ruiz De Mier; V. García-Montemayor; R. Ojeda López; C. Moyano Peregrín; S. Soriano Cabrera. Insuficiencia renal crónica. Medicine - Programa de Formación Médica Continuada Acreditado 2019, 12, 4683 -4692.
AMA StyleM.V. Pendón Ruiz De Mier, V. García-Montemayor, R. Ojeda López, C. Moyano Peregrín, S. Soriano Cabrera. Insuficiencia renal crónica. Medicine - Programa de Formación Médica Continuada Acreditado. 2019; 12 (79):4683-4692.
Chicago/Turabian StyleM.V. Pendón Ruiz De Mier; V. García-Montemayor; R. Ojeda López; C. Moyano Peregrín; S. Soriano Cabrera. 2019. "Insuficiencia renal crónica." Medicine - Programa de Formación Médica Continuada Acreditado 12, no. 79: 4683-4692.
Patients with advanced chronic kidney disease exhibit an increase in cardiovascular mortality. Recent works have shown that low levels of magnesium are associated with increased cardiovascular and all-cause mortality in hemodialysis patients. Epidemiological studies suggest an influence of low levels of magnesium on the occurrence of cardiovascular disease, which is also observed in the normal population. Magnesium is involved in critical cellular events such as apoptosis and oxidative stress. It also participates in a number of enzymatic reactions. In animal models of uremia, dietary supplementation of magnesium reduces vascular calcifications and mortality; in vitro, an increase of magnesium concentration decreases osteogenic transdifferentiation of vascular smooth muscle cells. Therefore, it may be appropriate to evaluate whether magnesium replacement should be administered in an attempt to reduce vascular damage and mortality in the uremic population In the present manuscript, we will review the magnesium homeostasis, the involvement of magnesium in enzymatic reactions, apoptosis and oxidative stress and the clinical association between magnesium and cardiovascular disease in the general population and in the context of chronic kidney disease. We will also analyze the role of magnesium on kidney function. Finally, the experimental evidence of the beneficial effects of magnesium replacement in chronic kidney disease will be thoroughly described.
Juan R. Muñoz-Castañeda; María V. Pendón-Ruiz De Mier; Mariano Rodríguez; María E. Rodríguez-Ortiz. Magnesium Replacement to Protect Cardiovascular and Kidney Damage? Lack of Prospective Clinical Trials. International Journal of Molecular Sciences 2018, 19, 664 .
AMA StyleJuan R. Muñoz-Castañeda, María V. Pendón-Ruiz De Mier, Mariano Rodríguez, María E. Rodríguez-Ortiz. Magnesium Replacement to Protect Cardiovascular and Kidney Damage? Lack of Prospective Clinical Trials. International Journal of Molecular Sciences. 2018; 19 (3):664.
Chicago/Turabian StyleJuan R. Muñoz-Castañeda; María V. Pendón-Ruiz De Mier; Mariano Rodríguez; María E. Rodríguez-Ortiz. 2018. "Magnesium Replacement to Protect Cardiovascular and Kidney Damage? Lack of Prospective Clinical Trials." International Journal of Molecular Sciences 19, no. 3: 664.
SOC occurs more frequently than other malignancies among renal transplant patients. NMSC has better survival and prognosis. Older patients and prolonged graft function have a greater risk of developing malignancies.
V. Pendón-Ruiz de Mier; M.D. Navarro Cabello; S. Martínez Vaquera; M. Lopez-Andreu; M.L. Aguera Morales; A. Rodriguez-Benot; P. Aljama Garcia. Incidence and Long-Term Prognosis of Cancer After Kidney Transplantation. Transplantation Proceedings 2015, 47, 2618 -2621.
AMA StyleV. Pendón-Ruiz de Mier, M.D. Navarro Cabello, S. Martínez Vaquera, M. Lopez-Andreu, M.L. Aguera Morales, A. Rodriguez-Benot, P. Aljama Garcia. Incidence and Long-Term Prognosis of Cancer After Kidney Transplantation. Transplantation Proceedings. 2015; 47 (9):2618-2621.
Chicago/Turabian StyleV. Pendón-Ruiz de Mier; M.D. Navarro Cabello; S. Martínez Vaquera; M. Lopez-Andreu; M.L. Aguera Morales; A. Rodriguez-Benot; P. Aljama Garcia. 2015. "Incidence and Long-Term Prognosis of Cancer After Kidney Transplantation." Transplantation Proceedings 47, no. 9: 2618-2621.